Featured News

Renewed Contract for Chemopreventive Agent Repository

Pharmaceutical Sciences

MRIGlobal has been awarded a 5-year, $19.9 million contract from the National Institutes of Health (NIH)/National Cancer Institute (NCI)/Division of Cancer Prevention to continue to operate the Centralized Chemopreventive Agent Repository and Drug Chemistry Support program.   

This program serves as a centralized source of agents for use in studies by the Division of Cancer Prevention (DCP) and to support the translation of promising laboratory discoveries into effective interventions for the prevention or reduction of cancer.

MRIGlobal’s Repository Services

The repository program has responsibilities of acquiring, tracking, storage, maintenance, testing, quality control, and distribution of these investigational agents to NCI DCP designated preclinical and Phase 0/I/II cancer prevention clinical investigation sites and complements MRIGlobal’s well-established programs supporting the National Cancer Institute (NCI). 

“MRIGlobal is proud to continue our work with NIH/NCI and cancer researchers around the world who utilize our Repository and associated services,” said MRIGlobal President and CEO Thomas M. Sack, Ph.D. “Our commitment to cancer research is long-standing. Our cancer research and support with the National Cancer Institute dates back to 1948.”

To learn more about our repository services, visit our website here.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800026I (UPIID: 75N91018D00026).